Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | HTR7 | P34969 | 1/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | ADRB2 | P07550 | 3/20 | 0.38 |
| ▸ | ADRB1 | P08588 | 3/20 | 0.38 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 3/20 | 0.37 |
| ▸ | NPC1 | O15118 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5371265 | 1.00 | KMT2A (0.48) | KMT2AMEN1SMN1; SMN2GAAATM | |
| SCHEMBL29671577 | 0.78 | KMT2A (0.59) | KMT2AMEN1SMN1; SMN2GAAATM | |
| SCHEMBL6468101 | 0.78 | KMT2A (0.59) | KMT2AMEN1SMN1; SMN2GAAATM | |
| SCHEMBL27514088 | 0.77 | KMT2A (0.51) | KMT2AMEN1SMN1; SMN2GAAATM | |
| SCHEMBL5370551 | 0.76 | MTNR1A (0.63) | KMT2AMEN1SMN1; SMN2GAAATM | |
| SCHEMBL5370545 | 0.76 | MTNR1A (0.63) | KMT2AMEN1SMN1; SMN2GAAATM | |
| SCHEMBL7383196 | 0.76 | MTNR1A (0.51) | KMT2AMEN1SMN1; SMN2GAAATM | |
| SCHEMBL7383193 | 0.76 | MTNR1A (0.51) | KMT2AMEN1SMN1; SMN2GAAATM | |
| SCHEMBL8817579 | 0.75 | HTR1B (0.49) | KMT2AMEN1GAASIGMAR1ADRB2 | |
| SCHEMBL20385338 | 0.75 | MAOA (0.65) | KMT2AMEN1SIGMAR1ADRB2ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7186715-B2 | Piperazine- and piperidine-derivatives as melanocortin receptor agonists | ELI LILLY AND COMPANY (US) | 2007-03-06 | — | — | US | disclosed |
| EP-1370558-B1 | PIPERAZINE- AND PIPERIDINE-DERIVATIVES AS MELANOCORTIN RECEPTOR AGONISTS | LILLY CO ELI (US) | 2005-08-24 | — | — | EP | disclosed |
| US-20040082590-A1 | Piperazine- and piperidine-derivatives as melanocortin receptor agonists | ELI LILLY AND COMPANY | 2004-04-29 | — | — | US | disclosed |
| EP-1370558-A1 | PIPERAZINE- AND PIPERIDINE-DERIVATIVES AS MELANOCORTIN RECEPTOR AGONISTS | ELI LILLY AND COMPANY (US) | 2003-12-17 | — | — | EP | disclosed |
| WO-2002059117-A1 | PIPERAZINE- AND PIPERIDINE-DERIVATIVES AS MELANOCORTIN RECEPTOR AGONISTS | ELI LILLY AND COMPANY (US) | 2002-08-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082590-A1 | Piperazine- and piperidine-derivatives as melanocortin receptor agonists | MC1R, MC4R, MC5R | KMT2A 2374/4885MEN1 1206/4885SMN1; SMN2 3078/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.